

CIRCULAR DATED 8 OCTOBER 2026

THIS CIRCULAR IS IMPORTANT AND REQUIRES YOUR IMMEDIATE ATTENTION.

This Circular is issued by Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited (formerly known as Tianjin Zhong Xin Pharmaceutical Group Corporation Limited) (the “Company”). **If you are in any doubt as to the action you should take, you should consult your stockbroker, bank manager, solicitor, accountant or other professional adviser(s) immediately.**

If you have sold all your shares in the capital of the Company, you should immediately hand this Circular, the Notice of Extraordinary General Meeting and the accompanying Proxy Form to the purchaser or to the bank, stockbroker or agent through whom the sale or transfer was effected, for onward transmission to the purchaser or transferee.

The Singapore Exchange Securities Trading Limited assumes no responsibility for the accuracy of any statements or opinions made or reports contained in this Circular.



**TIANJIN PHARMACEUTICAL DA REN TANG
GROUP CORPORATION LIMITED**

(Incorporated in the People's Republic of China)
(Company Registration No.: 91120000103100784F)

CIRCULAR TO SHAREHOLDERS

in relation to

**THE PROPOSED AMENDMENTS TO THE ARTICLES OF ASSOCIATION OF THE COMPANY
AND THE APPLICATION FOR CHANGES IN THE INDUSTRIAL AND COMMERCIAL
REGISTRATION**

IMPORTANT DATES AND TIMES

Last date and time for lodgement of Proxy Form	:	21 October 2026 at 2:00 p.m.
Date and time of Extraordinary General Meeting	:	23 October 2026 at 2:00 p.m.
Place of Extraordinary General Meeting	:	171 Chin Swee Road, CES Centre, #02-07/08, Singapore 169877

TABLE OF CONTENTS

DEFINITIONS	3
LETTER TO SHAREHOLDERS	8
1. INTRODUCTION	8
2. THE PROPOSED AOA AMENDMENTS	9
3. DIRECTORS' AND SUBSTANTIAL SHAREHOLDERS' INTERESTS	18
4. DIRECTORS' RECOMMENDATIONS	19
5. EXTRAORDINARY GENERAL MEETING	19
6. ACTION TO BE TAKEN BY S-SHARE SHAREHOLDERS	20
7. DIRECTORS' RESPONSIBILITY STATEMENT	20
8. DOCUMENT AVAILABLE FOR INSPECTION	21
NOTICE OF EXTRAORDINARY GENERAL MEETING	N-1
PROXY FORM	

DEFINITIONS

The following definitions apply throughout this Circular unless the context otherwise requires or otherwise stated:

<i>“2026 2nd EGM”</i>	:	The 2 nd EGM of the Company in 2026 to be held at the meeting room of Da Ren Tang Mansion, No. 17 Baidi Road, Nankai District, Tianjin, the PRC 300193 (concurrently, via video conferencing at 171 Chin Swee Road, CES Centre, #02-07/08, Singapore 169877 for S-Share Shareholders in Singapore) on Friday, 23 October 2026 at 2:00 p.m.
<i>“A-Shares”</i>	:	Ordinary shares issued by the Company under the PRC Company Law, comprising shares issued to natural and legal persons in the PRC and which are denominated in RMB and listed on the SSE
<i>“A-Share Shareholders”</i>	:	Holders of A-Shares
<i>“AOA” or “Articles of Association”</i>	:	The articles of association of the Company, as amended, modified and/or supplemented from time to time
<i>“associated company”</i>	:	In relation to a corporation, means: <ul style="list-style-type: none">(a) any corporation in which the corporation or its subsidiary has, or the corporation and its subsidiary together have, a direct interest in voting shares of not less than twenty per cent. (20%) but not more than fifty per cent. (50%) of the total votes attached to all voting shares in the corporation; or(b) any corporation, other than a subsidiary of the corporation or a corporation which is an associated company by virtue of paragraph (a), the policies of which the corporation or its subsidiary, or the corporation together with its subsidiary, is or are able to control or influence materially
<i>“Board” or “Board of Directors”</i>	:	The board of Directors of the Company from time to time, which, as at the Latest Practicable Date, comprises Ms. Wang Lei, Mr. Guo Min, Mr. Zhou Hong, Mr. Shang Mingjie, Ms. Mao Weiwen, Mr. Xing Jianhua, Mr. Yeo Guat Kwang, Ms. Zhai Shuping, and Mr. Zhong Ming
<i>“Business Scope Catalogue”</i>	:	The Catalogue of Standardised Expressions for Business Scope (《经营范围规范表述目录》) issued by the SAMR, as in force as at the Latest Practicable Date
<i>“CDP”</i>	:	The Central Depository (Pte) Limited
<i>“Circular”</i>	:	This circular dated 8 October 2026
<i>“Company”</i>	:	Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited

DEFINITIONS

<i>“control”</i>	:	The capacity to dominate decision-making, directly or indirectly, in relation to the financial and operating policies of a company
<i>“Controlling Shareholder”</i>	:	<p>A person who:</p> <p>(a) holds directly or indirectly fifteen per cent. (15%) or more of the total voting rights in the Company. The SGX-ST may determine that a person who satisfies this paragraph is not a controlling shareholder; or</p> <p>(b) in fact exercises control over the Company</p>
<i>“CSRC”</i>	:	China Securities Regulatory Commission (中国证券监督管理委员会)
<i>“Directors”</i>	:	The directors of the Company as at the Latest Practicable Date, and <i>“Director”</i> shall be construed accordingly
<i>“EGM” or “Extraordinary General Meeting”</i>	:	An extraordinary general meeting of the Company
<i>“Group”</i>	:	The Company and its subsidiaries
<i>“Latest Practicable Date”</i>	:	28 September 2026, being the latest practicable date prior to the despatch of this Circular
<i>“Listing Manual”</i>	:	The listing manual of the SGX-ST, as amended, modified and/or supplemented from time to time
<i>“Notice of EGM”</i>	:	The notice of the 2026 2 nd EGM dated 8 October 2026
<i>“PRC”</i>	:	People’s Republic of China
<i>“PRC Company Law”</i>	:	The Company Law of the PRC (《中华人民共和国公司法》), as amended, modified and/or supplemented from time to time
<i>“PRC Laws”</i>	:	All laws, regulations, decrees or other acts of a legally binding nature that are in force from time to time in the PRC, including any amendment or substitution thereof
<i>“Proposed Adjustment to Business Scope”</i>	:	The proposed addition of certain business activities to the existing business scope of the Company, as described in Section 2.1(b) of this Circular
<i>“Proposed AOA Amendments”</i>	:	<p>The following proposed amendments to the existing Articles of Association, collectively:</p> <p>(a) the proposed amendments to Article 4 relating to the legal representative of the Company; and</p> <p>(b) the proposed amendments to Article 12 relating to the business scope of the Company,</p> <p>as further elaborated in Section 2 of this Circular</p>

DEFINITIONS

<i>“Proxy Form”</i>	:	The proxy form in respect of the 2026 2 nd EGM
<i>“Register of Members”</i>	:	The register of members of the Company as maintained by the Company’s S-Shares Registrar and Singapore Shares Transfer Office, Boardroom Corporate & Advisory Services Pte. Ltd.
<i>“Restricted A-Shares”</i>	:	A-Shares granted under the Scheme which shall be subject to the terms and conditions of the Scheme
<i>“S-Shares”</i>	:	Ordinary shares issued by the Company under the PRC Company Law, comprising shares issued to natural and legal persons in countries other than the PRC and which are denominated in US\$ and are listed on the Official List of the SGX-ST
<i>“S-Share Shareholders”</i>	:	Holders of S-Shares
<i>“SAMR”</i>	:	State Administration for Market Regulation (国家市场监督管理总局)
<i>“Scheme”</i>	:	The 2019 Restricted A-Share Incentive Scheme (2019年A股限制性股票计划) of the Company, which was established to further improve the long-term incentive mechanism of the Company, attract and retain outstanding talents, fully motivate the key personnel of the Company, and align the interests of the Shareholders and the Company with the individual interests of the members of the management team of the Company, so that all the aforementioned parties will make a joint effort for the long-term development of the Company. The incentive instruments issued under the Scheme are A-Shares only, and those eligible to participate in the Scheme include directors, members of senior management, members of the Company’s management team whom the Board considers should be motivated, leading-level scientific research experts, core personnel for scientific research and technology, and members of the core management team of the subordinate enterprises of the Company (excluding the Company’s associated companies) ¹
<i>“securities accounts”</i>	:	The securities account maintained with CDP, but not including the securities accounts maintained with a Depository Agent
<i>“SFA”</i>	:	The Securities and Futures Act 2001 of Singapore, as amended, modified and/or supplemented from time to time
<i>“SGXNet”</i>	:	Singapore Exchange Network, the corporate announcement system maintained by the SGX-ST for the submission of information and announcements by listed companies

¹ For further details of the Scheme, please refer to the Company’s circular dated 15 November 2019.

DEFINITIONS

“SGX-ST”	:	Singapore Exchange Securities Trading Limited
“Shareholders”	:	Registered holders of Shares (comprising A-Share Shareholders and S-Share Shareholders) except that where the registered holder is CDP, the term “Shareholders” in relation to Shares held by CDP shall mean the persons named as Depositors in the Depository Register maintained by CDP and to whose securities accounts such Shares are credited
“Shares”	:	Ordinary shares in the capital of the Company, comprising A-Shares and S-Shares
“SSE”	:	Shanghai Stock Exchange
“SSE Listing Rules”	:	The Listing Rules of Shanghai Stock Exchange (《上海证券交易所股票上市规则》), as amended, modified and/or supplemented from time to time
“subsidiaries”	:	The subsidiaries of a corporation as determined in accordance with the laws of the PRC or Singapore (as the case may be), and “subsidiary” shall be construed accordingly
“Substantial Shareholder”	:	A person who has an interest or interests in one (1) or more voting Shares (excluding treasury shares) in the Company, and the total votes attached to that Share, or those Shares, represent not less than five per cent. (5%) of the total votes attached to all the voting Shares (excluding treasury shares) in the Company
“Tianjin MSAC”	:	Tianjin Municipal Market Supervision and Administration Commission (天津市市场监督管理委员会)
“TPH”	:	Tianjin Pharmaceutical Holdings Co., Ltd. (天津市医药集团有限公司), the Controlling Shareholder of the Company holding approximately 43.091% of the issued share capital of the Company as at the Latest Practicable Date

Currencies, units and others

“RMB”	:	Renminbi, being the lawful currency of the PRC
“S\$”	:	Singapore Dollars, being the lawful currency of the Republic of Singapore
“US\$”	:	United States Dollars, being the lawful currency of the United States of America
“%” or “per cent.”	:	Percentage or per centum

DEFINITIONS

The terms “**Depositor**”, “**Depository**”, “**Depository Register**” and “**Depository Agent**” shall have the meanings ascribed to them respectively in Section 81SF of the SFA.

Words importing the singular shall, where applicable, include the plural and *vice versa*. Words importing the masculine gender shall, where applicable, include the feminine and neuter genders and *vice versa*. References to persons shall, where applicable, include corporations.

Any reference in this Circular to any enactment is a reference to that enactment as for the time being amended or re-enacted. Any term defined under the Listing Manual, the SFA or any statutory modification thereof and not otherwise defined in this Circular shall, where applicable, have the same meaning ascribed to it under the Listing Manual, the SFA or any statutory modifications thereof, as the case may be, unless the context otherwise requires.

Any reference to a time of a day in this Circular is a reference to Singapore time, unless otherwise stated.

Any discrepancies in this Circular between the sum of the figures stated and the totals thereof are due to rounding. Accordingly, figures shown as totals in this Circular may not be an arithmetic aggregation of the figures which precede them.

The English names of certain PRC companies, entities and authorities referred to in this Circular are unofficial translations of their Chinese names, as such companies, entities and authorities are not required to have official English names, and are provided for identification purposes only. In the event of any inconsistency or discrepancy between the Chinese names and their English translations, the Chinese names shall prevail.

LETTER TO SHAREHOLDERS

TIANJIN PHARMACEUTICAL DA REN TANG GROUP CORPORATION LIMITED

(Incorporated in the People's Republic of China)
(Company Registration No.: 91120000103100784F)

Board of Directors

Ms. Wang Lei

(Chairman and Executive Director)

Mr. Guo Min

(Executive Director)

Mr. Zhou Hong

(Executive Director)

Mr. Shang Mingjie

(Executive Director)

Ms. Mao Weiwen

(Non-Executive and Non-Independent Director)

Mr. Xing Jianhua

(Non-Executive and Non-Independent Director)

Mr. Yeo Guat Kwang

(Lead Independent and Non-Executive Director)

Ms. Zhai Shuping

(Independent and Non-Executive Director)

Mr. Zhong Ming

(Independent and Non-Executive Director)

Registered Office

17 Baidi Road,
Nankai District,
Tianjin, the PRC

8 October 2026

To: The Shareholders of Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited

Dear Sir/Madam

THE PROPOSED AMENDMENTS TO THE ARTICLES OF ASSOCIATION OF THE COMPANY AND THE APPLICATION FOR CHANGES IN THE INDUSTRIAL AND COMMERCIAL REGISTRATION

1. INTRODUCTION

1.1 2026 2nd EGM

The Directors are convening the 2026 2nd EGM to be held at the meeting room of Da Ren Tang Mansion, No. 17 Baidi Road, Nankai District, Tianjin, the PRC 300193 (concurrently, via video conferencing at 171 Chin Swee Road, CES Centre, #02-07/08, Singapore 169877 for S-Share Shareholders in Singapore) on Friday, 23 October 2026 at 2:00 p.m. to seek Shareholders' approval for the Proposed AOA Amendments and the application for changes in the industrial and commercial registration, as further elaborated in Section 2 below.

The Notice of EGM is set out on pages N-1 to N-3 of this Circular.

LETTER TO SHAREHOLDERS

1.2 Purpose of this Circular

The purpose of this Circular is to provide Shareholders with information pertaining to, and to seek Shareholders' approval for, the Proposed AOA Amendments.

If you are in any doubt as to the action you should take, you should consult your stockbroker, bank manager, solicitor, accountant or other professional adviser(s) immediately.

1.3 SGX-ST

The SGX-ST assumes no responsibility for the accuracy of any statements or opinions made or reports contained in this Circular.

1.4 Legal Adviser

Shook Lin & Bok LLP is the legal adviser to the Company as to Singapore law in relation to the Proposed AOA Amendments.

2. THE PROPOSED AOA AMENDMENTS

2.1 Background and Rationale

(a) Proposed Amendments to Article 4 of the Articles of Association

Article 4 of the existing Articles of Association provides that the legal representative of the Company is the Chairman of the Board.

Under the PRC Company Law (as revised with effect from 1 July 2024 and in force as at the Latest Practicable Date), the legal representative of a company shall, in accordance with its articles of association, be assumed by a director or manager who represents the company in the execution of the company's affairs.

Following the appointment of Mr. Chen Hong as the General Manager of the Company with effect from 4 September 2026, and having regard to the Company's current corporate governance arrangements and its management and operational needs, the Company considers it appropriate for the General Manager, who is responsible for the day-to-day management and operations of the Company, to replace the Chairman of the Board as the legal representative of the Company. The proposed change is intended to better align the role of the legal representative with the Company's management and operational functions and enhance the delineation of responsibilities within the Company's governance structure. As the Articles of Association prescribe who shall serve as the legal representative of the Company, the proposed change requires a corresponding amendment to the Articles of Association and the relevant change in industrial and commercial registration.

LETTER TO SHAREHOLDERS

(b) Proposed Amendments to Article 12 of the Articles of Association

(i) Proposed Adjustment to Business Scope

Having regard to the Company's actual circumstances and business development needs, the Company proposes to adjust its business scope by adding the following business activities:

- (A) marketing planning;
- (B) market research (excluding foreign-related surveys);
- (C) technical services, technology development, technical consultancy, technology exchange, technology transfer and technology promotion;
- (D) software development;
- (E) data processing and storage support services; and
- (F) information system operation and maintenance services.

The Proposed Adjustment to Business Scope is intended to accommodate the Company's current business development needs. In particular, the Company's Digital and IT Centre has, over an extended period, developed expertise, operational capabilities, digital products and related solutions in the areas covered by items (C) to (F) above, primarily in support of the Group's businesses. Such capabilities may, where appropriate, be commercialised through the provision of relevant technical services, technology development and related services, software development, data processing and storage support services, and information system operation and maintenance services to third parties.

In relation to software development, the Digital and IT Centre undertakes software development both in-house and in collaboration with external technology partners, and the Company holds multiple software copyrights. In relation to data processing, the Digital and IT Centre has established a data platform and a master data system, has attained Level 3 certification under the Data Management Capability Maturity Model (DCMM), and has data products listed on the Northern China Data Exchange (北方大数据交易中心). In relation to information system operation and maintenance, it provides stable support for various Group-level systems, including the Group's social customer relationship management (SCRM) system, procurement supplier relationship management (SRM) system and industrial enterprise resource planning (ERP) system. In relation to information technology consultancy, it has undertaken strategic planning for the Group's digital and intelligent transformation and has provided information technology-related training to more than 10,000 participants in aggregate.

The Digital and IT Centre is supported by professional teams covering software development, data management, system operation and maintenance, and information technology consultancy, together with a business partnering mechanism. Its operations are also supported by the Group's existing digital infrastructure, including its hybrid cloud and data platform, standardised master data and listed data products. The Company also maintains collaborations with

LETTER TO SHAREHOLDERS

technology and academic partners, including Huawei Cloud, Tianjin University of Traditional Chinese Medicine (天津中医药大学) and Tencent. Operationally, the Digital and IT Centre applies a full-lifecycle project management framework covering project initiation, implementation, acceptance and archiving, and multiple Group-level systems operate concurrently and on a stable basis under this framework.

The Company currently intends for the Digital and IT Centre to continue to focus primarily on supporting and enabling the Group's core businesses, and does not presently intend for it to become a material business line or revenue-generating segment of the Group. In the course of supporting the Group's core businesses, the Digital and IT Centre may also develop mature digital products and solutions capable of external deployment, which the Company may subsequently offer to third parties where appropriate. The Proposed Adjustment to Business Scope is intended principally to enable the Company to utilise its available digital and information technology resources and capabilities to provide services such as data processing, software development, information system operation and maintenance, and information technology training and consultancy services to third parties on a fee basis.

In addition, the Proposed Adjustment to Business Scope will enable the Company's marketing team to leverage its existing capabilities and experience to provide marketing planning, marketing promotion, market research and other marketing-related services to third parties.

Under Article 9 of the PRC Company Law (as in force as at the Latest Practicable Date), the business scope of a company shall be prescribed by its articles of association and a company may amend its articles of association to change its business scope. Accordingly, in order to facilitate the carrying out of the above activities, the Company proposes to expand its business scope and make the corresponding amendments to its Articles of Association.

The Proposed Adjustment to Business Scope will not result in any change to the principal business activities of the Company.

(ii) Standardisation of Business Scope Descriptions

In connection with the Proposed Adjustment to Business Scope and the corresponding changes in the Company's industrial and commercial registration, the Company also proposes to standardise the descriptions of its existing business scope in accordance with the applicable business scope registration requirements and the Catalogue of Standardised Expressions for Business Scope (《经营范围规范表述目录》) (i.e. the Business Scope Catalogue) issued by the State Administration for Market Regulation (国家市场监督管理总局) (i.e. the SAMR), as in force as at the Latest Practicable Date.

The business scope set out below in Article 12 (as proposed to be amended) shall be subject to the items as approved by, and registered with, the Tianjin Municipal Market Supervision and Administration Commission (天津市市场监督管理委员会) (i.e. Tianjin MSAC).

LETTER TO SHAREHOLDERS

As mentioned in the Company's circular dated 28 November 2025,² given the recent changes in the regulatory framework in the PRC, the Company is undertaking a comprehensive review of its Articles of Association, together with the Rules of Procedure of the General Meetings, the Rules of Procedure of the Board of Directors, and other corporate governance policies or rules (the "**Comprehensive Review**"), to update and streamline the provisions of such documents to be in line with the prevailing PRC Laws. The Comprehensive Review will also include updates to the Articles of Association for consistency with the listing rules set out in the Listing Manual prevailing at the time of the Comprehensive Review. The Comprehensive Review is expected to be completed, and the resulting amendments are expected to be submitted for Shareholders' approval, by the end of 2026.

In view of the Company's current corporate governance, business and registration needs described above, the Company proposes to proceed with the amendments to Articles 4 and 12 of the existing Articles of Association at this stage, separately from and ahead of the Comprehensive Review.

2.2 Amendments to the Articles of Association

The proposed amendments to Articles 4 and 12 of the existing Articles of Association are set out below (with insertions in bold and underline, and deletions in bold strikethrough):

Before the Proposed AOA Amendments	After the Proposed AOA Amendments
Article 4 The legal representative of the Company is the Chairman of the Board of Directors.	Article 4 <u>The General Manager shall be the legal representative of the Company.</u> The legal representative of the Company is the Chairman of the Board of Directors. <u>If the General Manager resigns from office, he or she shall be deemed to have resigned as the legal representative of the Company simultaneously.</u> <u>If the legal representative resigns from office, the Company shall designate a new legal representative within thirty (30) days from the date of such resignation.</u>
Article 12 The business scope of the Company shall be subject to the items as approved by the competent company registration authority.	Article 12 The business scope of the Company shall be subject to the items as approved by the competent company registration authority.

2 For further information, please refer to the Company's circular dated 28 November 2025.

LETTER TO SHAREHOLDERS

Before the Proposed AOA Amendments	After the Proposed AOA Amendments
<p>The business scope of the Company includes: production of Chinese traditional herbal medicine, Chinese traditional medicine, herbal pieces, western pharmaceutical preparation and chemical medicinal feedstock; processing, manufacturing, wholesale and retail of chemical preparation, new herbal medicinal products, medical apparatus and instruments, nutritional supplement and chemical reagents; processing and other logistics in relation to traditional Chinese medicinal products; purchases and sales through agents, and wholesale and retail of hygienic products, exercise machines, disinfection supplies for daily life and environment hygiene, skin protection medical products, general merchandise, clothes, shoes and hats, and home appliances; storage, advertising, technology development and transfer, economic information consultation service, house renting; purchases and sales through agents, and wholesale and retail of computers, software and analytical instruments; retail of family planning supplies; renting of medical equipment; exports of self-produced products and technologies; imports of feedstock, supplementary raw material, apparatus and instruments, machinery equipment, spare parts and corresponding technologies for the production of the Company (except commodities and technologies which are prohibited to be imported or exported by the PRC government or the sale and/or operation of which are limited to state-owned enterprises); business of processing with imported materials and forms of OEM and compensation trades; purchases of Chinese traditional medicines. Business items to be conducted/operated by branches/divisions/subsidiaries of the Company: medical packaging material, veterinary, bait additives, feed, bait, production of drugs for livestock, production of feed additives, livestock breeding, fresh water animal breeding and planting, catering, conference services;</p>	<p>The business scope of the Company includes:</p> <p><u>Licensed items: pharmaceutical manufacturing; contract manufacturing of pharmaceuticals; wholesale of pharmaceuticals; retail of pharmaceuticals; import and export of pharmaceuticals; operation of Class III medical devices; decoction services for prepared Chinese medicinal slices; internet information services; internet information services relating to pharmaceuticals; internet information services relating to medical devices; Class II value-added telecommunications services; food production; food sales; production of health food; production of disinfectants (excluding hazardous chemicals); road freight transportation (excluding dangerous goods); and printing of packaging and decorative printed matter. (For business activities that are subject to approval under applicable laws and regulations, such activities shall be carried out only upon obtaining approval from the relevant authorities. The specific business items shall be subject to the relevant approval documents or licences issued by the relevant authorities.)</u></p> <p><u>General items: marketing planning; market research (excluding foreign-related surveys); technical services, technology development, technical consultancy, technology exchange, technology transfer and technology promotion; software development; data processing and storage support services; information system operation and maintenance services; sale of Class I medical devices; sale of Class II medical devices; sale of sanitary products and disposable medical products; sale of personal hygiene products; sale of disinfectants (excluding hazardous chemicals); sale</u></p>

LETTER TO SHAREHOLDERS

Before the Proposed AOA Amendments	After the Proposed AOA Amendments
<p>retail of standard packaged food, edible oil, non-staple food, flavor; purified water and hygienic products; standard packaged drinking water; production and sales of bottle water; beverage; powder drinks, production and sales of tea drinks; operation limited only to branches: sales of antibiotics and bio-medicines and chemical medicines; The following business items may only be conducted/operated by branches/divisions/subsidiaries of the Company: medical diagnoses and treatment; medical tests, traditional Chinese medicine department, internal medicine, paediatrics, dermatology, Chinese Acupuncture, biological medicines, diagnostic medicine, sales of the second class psychoactive drugs; packaging and printing; road transportation; purchases and sales through agents, wholesale and retail of wines and alcohol, sugar, tea, beverage and bee products; narcotic drug (only limited to pericarpium papaveris); toxic drugs for medical use; protein assimilation agent; wholesale of peptide hormone; the sales of food, pre-packaged food, unpacked food; research, development and sales of biological engineering and biological products, chemical products (except for dangerous goods); wholesale of health food (tablets, hard gelatine capsules, teabag, oral use); wholesale and retail of edible agricultural products (as licensed); and scientific research and technical services (If the government has formulated monopoly operation over any of the abovementioned business items, the company shall comply with the relevant regulations).</p> <p>Business operation mode: processing and manufacturing, import and export, wholesale and retail services.</p>	<p><u>of pre-packaged health food; wholesale of cosmetics; retail of cosmetics; sale of daily general merchandise; wholesale of clothing and apparel; retail of clothing and apparel; wholesale of footwear and headwear; retail of footwear and headwear; sale of household electrical appliances; sale of daily sundry goods; sale of daily necessities; sale of chemical products (excluding chemical products subject to licensing requirements); sale of specialty chemical products (excluding hazardous chemicals); manufacture of specialty chemical products (excluding hazardous chemicals); manufacture of basic chemical raw materials (excluding the manufacture of hazardous chemicals and other chemical products subject to licensing requirements); wholesale of edible agricultural products; retail of edible agricultural products; cultivation of Chinese medicinal herbs; purchase of Chinese medicinal herbs; purchase and sale of locally produced Chinese medicinal herbs (excluding prepared Chinese medicinal slices); leasing of non-residential real estate; housing leasing; leasing of machinery and equipment; warehousing equipment leasing services; office equipment leasing services; wholesale of computer software, hardware and ancillary equipment; retail of computer software, hardware and ancillary equipment; sale of instruments and meters; import and export of goods; import and export of technology; import and export agency services; import and export of food; primary processing of edible agricultural products; wholesale of protective equipment for medical personnel; retail of protective equipment for medical personnel; manufacture of daily-use masks (non-medical); sale of daily-use masks (non-medical); manufacture of pharmaceutical production equipment; sale of pharmaceutical production</u></p>

LETTER TO SHAREHOLDERS

Before the Proposed AOA Amendments	After the Proposed AOA Amendments
	<p>equipment; sale of drug testing instruments; sale of specialised packaging equipment; packaging services; general cargo warehousing services (excluding hazardous chemicals and other items subject to licensing or approval requirements); loading, unloading and handling; domestic freight forwarding agency services; road freight transportation by general freight vehicles with a gross vehicle weight of 4.5 tonnes or less (excluding online freight transportation and dangerous goods); manufacture of bio-based materials; sale of bio-based materials; research and development of bio-based material technology; research and development of new material technology; research, development and application of cell technology; medical research and experimental development (excluding the development and application of human stem cell technology and genetic diagnosis and treatment technology); manufacture of eco-environmental materials; sale of eco-environmental materials; sale of recycled resources; tree planting and cultivation business; and leasing of land use rights. (Except for items that are subject to approval in accordance with applicable laws and regulations, the Company may independently carry out the foregoing general business activities in accordance with law on the basis of its business licence.)</p> <p>production of Chinese traditional herbal medicine, Chinese traditional medicine, herbal pieces, western pharmaceutical preparation and chemical medicinal feedstock; processing, manufacturing, wholesale and retail of chemical preparation, new herbal medicinal products, medical apparatus and instruments, nutritional supplement and chemical reagents; processing and other logistics in</p>

LETTER TO SHAREHOLDERS

Before the Proposed AOA Amendments	After the Proposed AOA Amendments
	<p>relation to traditional Chinese medicinal products; purchases and sales through agents, and wholesale and retail of hygienic products, exercise machines, disinfection supplies for daily life and environment hygiene, skin protection medical products, general merchandise, clothes, shoes and hats, and home appliances; storage, advertising, technology development and transfer, economic information consultation service, house renting; purchases and sales through agents, and wholesale and retail of computers, software and analytical instruments; retail of family planning supplies; renting of medical equipment; exports of self-produced products and technologies; imports of feedstock, supplementary raw material, apparatus and instruments, machinery equipment, spare parts and corresponding technologies for the production of the Company (except commodities and technologies which are prohibited to be imported or exported by the PRC government or the sale and/or operation of which are limited to state-owned enterprises); business of processing with imported materials and forms of OEM and compensation trades; purchases of Chinese traditional medicines. Business items to be conducted/operated by branches/divisions/subsidiaries of the Company: medical packaging material, veterinary, bait additives, feed, bait, production of drugs for livestock, production of feed additives, livestock breeding, fresh water animal breeding and planting, catering, conference services; retail of standard packaged food, edible oil, non-staple food, flavor; purified water and hygienic products; standard packaged drinking water; production and sales of bottle water; beverage; powder drinks, production and sales of tea drinks; operation limited only to branches: sales of antibiotics and bio-medicines and chemical</p>

LETTER TO SHAREHOLDERS

Before the Proposed AOA Amendments	After the Proposed AOA Amendments
	<p>medicines; The following business items may only be conducted/operated by branches/divisions/subsidiaries of the Company: medical diagnoses and treatment; medical tests, traditional Chinese medicine department, internal medicine, paediatrics, dermatology, Chinese Acupuncture, biological medicines, diagnostic medicine, sales of the second class psychoactive drugs; packaging and printing; road transportation; purchases and sales through agents, wholesale and retail of wines and alcohol, sugar, tea, beverage and bee products; narcotic drug (only limited to pericarpium papaveris); toxic drugs for medical use; protein assimilation agent; wholesale of peptide hormone; the sales of food, pre-packaged food, unpacked food; research, development and sales of biological engineering and biological products, chemical products (except for dangerous goods); wholesale of health food (tablets, hard gelatine capsules, teabag, oral use); wholesale and retail of edible agricultural products (as licensed); and scientific research and technical services (If the government has formulated monopoly operation over any of the abovementioned business items, the company shall comply with the relevant regulations).</p> <p>Business operation mode: processing and manufacturing, import and export, wholesale and retail services.</p>

Save for the above amendments, all other provisions of the Articles of Association of the Company shall remain unchanged.

LETTER TO SHAREHOLDERS

For the avoidance of doubt, the Articles of Association are written in both Chinese and English, with the English version being a translation of the Chinese version. Both versions have equal force and effect, and the Chinese version shall prevail in the event of any inconsistency. As the Company is currently undertaking the Comprehensive Review, the Company will, upon completion of the Comprehensive Review, append the Articles of Association as amended in their entirety (in both Chinese and English), incorporating the Proposed AOA Amendments together with any further amendments arising from the Comprehensive Review, to a circular to be issued for a subsequent general meeting to be convened in due course later this year, at which such further amendments will be tabled for Shareholders' approval.

2.3 Compliance with Requirements under Rule 730(2) of the Listing Manual

Notwithstanding that the Comprehensive Review is still in progress, the Articles of Association comply with Appendix 2.2 to the Listing Manual (save that in respect of paragraph 10 of Appendix 2.2, the Company has obtained from the SGX-ST a waiver from compliance with the requirement under Rule 707(1) of the Listing Manual to hold the AGM within four (4) months from the financial year end, on an evergreen basis), and the Proposed AOA Amendments are consistent with the listing rules set out in the Listing Manual prevailing at the time of amendments and at the current time.

2.4 Application for Changes in the Industrial and Commercial Registration

Subject to the Proposed AOA Amendments being approved at the 2026 2nd EGM, the Company shall submit an application to the Tianjin MSAC to effect the corresponding changes to the Company's industrial and commercial registration.

2.5 Voting Threshold

Pursuant to Article 116 of the PRC Company Law (as in force as at the Latest Practicable Date), a resolution to amend the articles of association of a company shall require the approval of not less than two-thirds (2/3) of the voting rights held by the shareholders present at the general meeting.

Accordingly, the resolution relating to the Proposed AOA Amendments shall require the approval of not less than two-thirds (2/3) of the voting rights held by the Shareholders present in person or by proxy at the 2026 2nd EGM.

3. DIRECTORS' AND SUBSTANTIAL SHAREHOLDERS' INTERESTS

The details of the Directors' and Substantial Shareholders' interests in the Shares as at the Latest Practicable Date are set out below:

	Direct Interest		Deemed Interest	
	No of Shares	% ⁽¹⁾	No of Shares	% ⁽¹⁾
Directors				
Wang Lei	—	—	—	—
Guo Min	—	—	331,844,728	43.091

LETTER TO SHAREHOLDERS

	Direct Interest		Deemed Interest	
	No of Shares	% ⁽¹⁾	No of Shares	% ⁽¹⁾
Zhou Hong	23,800 ⁽²⁾	0.003	—	—
Shang Mingjie	—	—	—	—
Mao Weiwen	—	—	—	—
Xing Jianhua	—	—	—	—
Yeo Guat Kwang	—	—	—	—
Zhai Shuping	—	—	—	—
Zhong Ming	—	—	—	—

Substantial Shareholders (other than Substantial Shareholders who are Directors)

TPH	325,855,528	42.314	5,989,200 ⁽³⁾	0.777
-----	-------------	--------	--------------------------	-------

Notes:

- (1) Based on the total issued share capital of 770,094,356 Shares as at the Latest Practicable Date.
- (2) These are the Restricted A-Shares granted and issued under the Scheme.
- (3) Pursuant to Section 4 of the SFA, TPH is deemed interested in the 5,989,200 Shares in the capital of the Company held by its wholly-owned subsidiary, Jinyao Global Pte. Ltd. (formerly known as Tianjin Pharmaceutical (Singapore) International Investment Pte. Ltd.).

As at the Latest Practicable Date, none of the Directors and, to the best of the Directors' knowledge, none of the Substantial Shareholders has any interest, direct or indirect, in the Proposed AOA Amendments other than through their respective shareholdings in the Company (if any) as disclosed above.

4. DIRECTORS' RECOMMENDATIONS

The Directors, having considered, among other things, the background and rationale for, and the terms of, the Proposed AOA Amendments, are of the opinion that the Proposed AOA Amendments are in the best interests of the Company and its Shareholders as a whole. Accordingly, the Directors recommend that Shareholders vote in favour of the resolution relating to the Proposed AOA Amendments to be proposed at the 2026 2nd EGM.

5. EXTRAORDINARY GENERAL MEETING

The 2026 2nd EGM, notice of which is set out on pages N-1 to N-3 of this Circular, will be held at the meeting room of Da Ren Tang Mansion, No. 17 Baidi Road, Nankai District, Tianjin, the PRC 300193 (concurrently, via video conferencing at 171 Chin Swee Road, CES Centre, #02-07/08, Singapore 169877 for S-Share Shareholders in Singapore) on Friday, 23 October 2026 at 2:00 p.m. for the purpose of considering and, if thought fit, passing the resolution(s) (with or without modifications) as set out in the Notice of EGM.

LETTER TO SHAREHOLDERS

S-Share Shareholders may participate in the 2026 2nd EGM via the video conferencing at 171 Chin Swee Road, CES Centre, #02-07/08, Singapore 169877 for S-Share Shareholders in Singapore by:

- (a) attending the 2026 2nd EGM in person;
- (b) submitting substantial and relevant questions relating to the resolution(s) to be tabled for approval at the 2026 2nd EGM, in advance of, or at, the 2026 2nd EGM; and/or
- (c) voting at the 2026 2nd EGM (i) themselves, or (ii) through their duly appointed proxy(ies).

Details of the submission of questions and voting at the 2026 2nd EGM by Shareholders (including S-Share Shareholders) are set out in the Notice of EGM.

6. ACTION TO BE TAKEN BY S-SHARE SHAREHOLDERS

S-Share Shareholders who wish to vote but who are unable to attend the 2026 2nd EGM and wish to appoint a proxy or proxies to attend and vote at the 2026 2nd EGM on their behalf must complete, sign and return the Proxy Form in accordance with the instructions printed thereon as soon as possible and, in any event, ensure that it is received (i) by post at the office of the Company's S-Shares Registrar and Singapore Shares Transfer Office, Boardroom Corporate & Advisory Services Pte. Ltd., at 1 Harbourfront Avenue, Keppel Bay Tower #14-07, Singapore 098632, or (ii) by email at srs.proxy@boardroomlimited.com, no later than **2:00 p.m. on Wednesday, 21 October 2026**.

The completion and return of a Proxy Form by a S-Share Shareholder does not preclude such S-Share Shareholder from attending, speaking and voting in person at the 2026 2nd EGM should they subsequently decide to do so. In such an event, the appointment of the proxy(ies) for the 2026 2nd EGM will be deemed to be revoked upon the S-Share Shareholder's attendance at the 2026 2nd EGM in person, and the Company reserves the right to refuse to admit any person(s) appointed under the Proxy Form to the 2026 2nd EGM.

A S-Share Shareholder who intends to attend the 2026 2nd EGM must be registered in the Register of Members or, if the registered holder is CDP, must be named as a Depositor in the Depository Register, as at a time not earlier than forty-eight (48) hours before the 2026 2nd EGM.

7. DIRECTORS' RESPONSIBILITY STATEMENT

The Directors collectively and individually accept full responsibility for the accuracy of the information given in this Circular and confirm after making all reasonable enquiries that, to the best of their knowledge and belief, this Circular constitutes full and true disclosure of all material facts about the Proposed AOA Amendments and the Group, and the Directors are not aware of any facts the omission of which would make any statement in this Circular misleading.

Where information in this Circular has been extracted from published or otherwise publicly available sources or obtained from a named source, the sole responsibility of the Directors has been to ensure that such information has been accurately and correctly extracted from those sources and/or reproduced in this Circular in its proper form and context.

LETTER TO SHAREHOLDERS

8. DOCUMENT AVAILABLE FOR INSPECTION

A copy of the Articles of Association of the Company is available for inspection at the registered office of the Company at 17 Baidi Road, Nankai District, Tianjin, the PRC 300193, during normal business hours from the date of this Circular up to and including the date of the 2026 2nd EGM.

Yours faithfully

For and on behalf of the Board of Directors of

Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited

Wang Lei

Chairman of the Board

NOTICE OF EXTRAORDINARY GENERAL MEETING

TIANJIN PHARMACEUTICAL DA REN TANG GROUP CORPORATION LIMITED

(Formerly known as Tianjin Zhong Xin Pharmaceutical Group Corporation Limited)

(Incorporated in the People's Republic of China)

(Company Registration No.: 91120000103100784F)

(the “**Company**”)

NOTICE OF EXTRAORDINARY GENERAL MEETING

IMPORTANT NOTE FOR S-SHARE SHAREHOLDERS

The Company issued a notice of the Extraordinary General Meeting on 7 September 2026 in accordance with the notice period prescribed under applicable PRC law and its Articles of Association.

This updated notice of Extraordinary General Meeting, issued in compliance with the listing rules of the Singapore Exchange Securities Trading Limited, supersedes the notice announced by the Company on 7 September 2026.

NOTICE IS HEREBY GIVEN that an extraordinary general meeting (“**EGM**” or “**Extraordinary General Meeting**”) of the Company will be held at the meeting room of Da Ren Tang Mansion, No. 17 Baidi Road, Nankai District, Tianjin, the People's Republic of China (the “**PRC**”) 300193 (concurrently, via video conferencing at 171 Chin Swee Road, CES Centre, #02-07/08, Singapore 169877 for holders of the S-Shares (“**S-Share Shareholders**”) in Singapore) on Friday, 23 October 2026 at 2:00 p.m..

*Unless otherwise defined, all capitalised terms used in this Notice of EGM which are not defined herein shall have the same meanings ascribed to them in the circular issued by the Company to its Shareholders dated 8 October 2026 (the “**Circular**”).*

To consider and, if thought fit, approve the following resolution, with or without modifications:

Resolution: To consider and approve the proposed amendments to the Articles of Association of the Company and the application for changes in the industrial and commercial registration

By Order of the Board

Jiao Yan
Secretary to the Board of Directors
8 October 2026

NOTICE OF EXTRAORDINARY GENERAL MEETING

Notes:

1. The EGM will be held at the meeting room of Da Ren Tang Mansion, No. 17 Baidi Road, Nankai District, Tianjin, the PRC 300193 (concurrently, via video conferencing at 171 Chin Swee Road, CES Centre, #02-07/08, Singapore 169877 for S-Share Shareholders in Singapore) on Friday, 23 October 2026 at 2:00 p.m..
2. EGM documents. Printed copies of the circular dated 8 October 2026 issued by the Company (the “Circular”), which includes this updated notice of EGM (the “Notice of EGM”) and the accompanying Proxy Form, will be sent to S-Share Shareholders. The Circular, this Notice of EGM and the Proxy Form have also been, or will also be, made available via SGXNet and on the Company’s website at www.jydr.com.cn. S-Share Shareholders and investors are advised to check SGXNet and/or the Company’s website at www.jydr.com.cn regularly for the latest updates.
3. Shareholders’ questions and answers. S-Share Shareholders and duly appointed proxy or proxies will be able to attend the EGM in person and ask questions relating to the resolution(s) to be tabled for approval at the EGM.

However, S-Share Shareholders are encouraged to raise their questions (if any) as early as possible in advance of the EGM, and in any event by **5:00 p.m. on Sunday, 18 October 2026** (being not less than seven (7) calendar days after the date of the Notice of EGM) and can submit substantial and relevant questions relating to the resolution(s) to be tabled for approval at the EGM, in advance of the EGM, in the following manner:

- (a) by email to drt600329@163.com; or
- (b) by post to the Company’s S-Shares Registrar and Singapore Transfer Office, Boardroom Corporate & Advisory Services Pte. Ltd., at 1 Harbourfront Avenue, Keppel Bay Tower #14-07, Singapore 098632.

S-Share Shareholders who submit questions in advance of the EGM should provide their full name, address, contact number, email address and the manner in which they hold Shares (if you hold Shares directly, please provide your account number with The Central Depository (Pte) Limited; otherwise, please state if you hold your Shares through the Central Provident Fund Investment Scheme (“CPF”) or the Supplementary Retirement Scheme (“SRS”) or other Relevant Intermediary), for our verification purposes. “Relevant Intermediary” means (a) a banking corporation licensed under the Banking Act 1970 of Singapore or a wholly-owned subsidiary of such a banking corporation, whose business includes the provision of nominee services and who holds shares in that capacity; (b) a person holding a capital markets services licence to provide custodial services for securities under the Securities and Futures Act 2001 of Singapore and who holds shares in that capacity; or (c) the CPF Board established by the Central Provident Fund Act 1953 of Singapore, in respect of shares purchased under the subsidiary legislation made under that Act providing for the making of investments from the contributions and interest standing to the credit of members of the CPF, if the Board holds those shares in the capacity of an intermediary pursuant to or in accordance with that subsidiary legislation.

The Company will endeavour to answer all substantial and relevant questions in relation to the resolution(s) to be tabled for approval at the EGM prior to or at the EGM. **Where substantially similar questions are received, the Company may consolidate such questions and consequently not all questions may be individually addressed.**

The Company will also publish the minutes of the EGM, which will include substantial and relevant questions relating to the resolution(s) to be tabled for approval at the EGM and the responses from the Board and/or management of the Company to such questions, via SGXNet and on the Company’s website at www.jydr.com.cn within one (1) month after the date of the EGM.

4. Voting. A Shareholder (whether individual or corporate, including Relevant Intermediaries) who is entitled to attend and vote at the EGM may appoint one (1) or more persons (who need not also be Shareholder(s)) to act as his/her/its proxy(ies) to attend and vote on his/her/its behalf at the EGM. Where a Shareholder appoints more than one (1) proxy, the appointments shall be deemed to be alternative unless he/she/it specifies the proportion of his/her/its shareholding (expressed as a percentage of the whole) to be represented by each proxy.

If the appointor is a corporation, the instrument of proxy must be executed under seal or by the hand of its duly authorised officer or attorney.

A S-Share Shareholder (whether individual or corporate) can also choose to appoint the Chairman of the EGM as his/her/its proxy, but this is not mandatory. The Chairman of the EGM, as proxy, need not be a Shareholder of the Company. Where a S-Share Shareholder (whether individual or corporate) appoints the Chairman of the EGM as his/her/its proxy, he/she/it must give specific instructions as to voting, or abstentions from voting, in the Proxy Form. **In the absence of specific instructions, the appointment of the Chairman of the EGM as his/her/its proxy for that resolution will be treated as invalid.**

NOTICE OF EXTRAORDINARY GENERAL MEETING

Where a S-Share Shareholder (whether individual or corporate) appoints one (1) or more persons (other than the Chairman of the EGM) as his/her/its proxy(ies), he/she/it must give specific instructions as to voting, or abstentions from voting, in the Proxy Form. **In the absence of specific instructions, the proxy(ies) may vote or abstain from voting on the resolution(s) at his/her/their discretion.**

The Proxy Form has been, or will be, made available via SGXNet and may also be accessed at the Company's website at www.jydr.com.cn.

Investors who hold Shares under the CPF ("CPF Investor") and/or the SRS ("SRS Investor") (as applicable) and wish to vote should inform their respective CPF Agent Banks and/or SRS Operators to submit their votes at least **seven (7)** working days before the date of the EGM (i.e. by **5:00 p.m. on Tuesday, 13 October 2026**). **The Proxy Form is not valid for use by CPF Investors and SRS Investors and shall be ineffective for all intents and purposes if used or purported to be used by them.**

The duly completed Proxy Form must be submitted by S-Share Shareholders to the Company in the following manner:

- (a) if submitted by post, be lodged with the Company's S-Shares Registrar and Singapore Transfer Office, Boardroom Corporate & Advisory Services Pte. Ltd., at 1 Harbourfront Avenue, Keppel Bay Tower #14-07, Singapore 098632; or
- (b) if submitted electronically, via email to the Company's S-Shares Registrar and Singapore Transfer Office at srs.proxy@boardroomlimited.com,

in either case, by no later than **2:00 p.m. on Wednesday, 21 October 2026**.

S-Share Shareholders are strongly encouraged to submit completed Proxy Forms electronically via email.

A S-Share Shareholder who wishes to submit an instrument of proxy must first complete and sign the Proxy Form, before submitting it by post to the address provided above, or before scanning and sending it by email to the email address provided above. If a S-Share Shareholder is a corporation, the Proxy Form must be executed under seal or by the hand of its duly authorised officer or attorney.

The completion and return of the instrument appointing a proxy(ies) by a Shareholder does not preclude such Shareholder from attending, speaking and voting in person at the EGM if such Shareholder subsequently decides to do so. The appointment of the proxy(ies) for the EGM will be deemed to be revoked if the Shareholder attends the EGM in person and in such event, the Company reserves the right to refuse to admit any person or persons appointed under the relevant instrument appointing a proxy(ies) to the EGM.

- 5. The EGM in Tianjin, the PRC is expected to last for half a day and all accommodation and other expenses incurred by a Shareholder or his/her/its proxy(ies) in connection with his/her/its attendance at the EGM shall be borne by that Shareholder.
- 6. **Personal data privacy:** By (1) submitting a proxy form appointing a proxy(ies) and/or representative(s) to attend, speak and vote at the EGM and/or any adjournment thereof, (2) submitting any question prior to the EGM, a Shareholder of the Company (a) consents to the collection, use and disclosure of the Shareholder's personal data by the Company (or its agents or service providers) for the purposes of (i) the processing and administration by the Company (or its agents or service providers) of proxies and representatives appointed for the EGM (including any adjournment thereof), (ii) the preparation and compilation of the attendance lists, minutes and other documents relating to the EGM (including any adjournment thereof), (iii) the addressing of substantial and relevant questions relating to the resolution(s) to be tabled for approval at the EGM from Shareholders received prior to and/or at the EGM and if necessary, the follow-up with Shareholders in relation to such questions, and (iv) in order for the Company (or its agents or service providers) to comply with any applicable laws, listing rules, regulations and/or guidelines (collectively, the "**Purposes**"); (b) warrants that where a Shareholder discloses the personal data of such Shareholder's proxy(ies) and/or representative(s) to the Company (or its agents or service providers), such Shareholder has obtained the prior consent of such proxy(ies) and/or representative(s) for the collection, use and disclosure by the Company (or its agents or service providers) of the personal data of such proxy(ies) and/or representative(s) for the Purposes; and (c) agrees that the Shareholder will indemnify the Company in respect of any penalties, liabilities, claims, demands, losses and damages as a result of the Shareholder's breach of warranty.

PROXY FORM

TIANJIN PHARMACEUTICAL DA REN TANG GROUP CORPORATION LIMITED

(Formerly known as Tianjin Zhong Xin Pharmaceutical Group Corporation Limited)

(Incorporated in the People's Republic of China)

(Company Registration No.: 91120000103100784F)

(the "Company")

EXTRAORDINARY GENERAL MEETING PROXY FORM

(You are advised to read the notes below before completing this form)

IMPORTANT

- The EGM will be held at the meeting room of Da Ren Tang Mansion, No. 17 Baidi Road, Nankai District, Tianjin, the PRC 300193 (concurrently, via video conferencing at 171 Chin Swee Road, CES Centre, #02-07/08, Singapore 169877 for S-Share Shareholders in Singapore) on Friday, 23 October 2026 at 2:00 p.m..
- A S-Share Shareholder (whether individual or corporate) can choose to appoint the Chairman of the EGM as his/her/its proxy, but this is not mandatory. The Chairman of the EGM, as proxy, need not be a Shareholder of the Company. Where a S-Share Shareholder (whether individual or corporate) appoints the Chairman of the EGM as his/her/its proxy, he/she/it must give specific instructions as to voting, or abstentions from voting, in this Proxy Form. **In the absence of specific instructions, the appointment of the Chairman of the EGM as his/her/its proxy for that resolution will be treated as invalid.**
- Where a S-Share Shareholder (whether individual or corporate) appoints one (1) or more persons (other than the Chairman of the EGM) as his/her/its proxy(ies), he/she/it must give specific instructions as to voting, or abstentions from voting, in this Proxy Form. **In the absence of specific instructions, the proxy(ies) may vote or abstain from voting on the resolution(s) at his/her/their discretion.**
- Investors who hold Shares under the CPF ("CPF Investor") and/or the SRS ("SRS Investor") (as applicable) and wish to vote should inform their respective CPF Agent Banks and/or SRS Operators to submit their votes at least **seven (7)** working days before the date of the EGM (i.e. by 5:00 p.m. on Tuesday, 13 October 2026). **The Proxy Form is not valid for use by CPF Investors and SRS Investors and shall be ineffective for all intents and purposes if used or purported to be used by them.**
- Personal Data Privacy:** By submitting this Proxy Form, the S-Share Shareholders accepts and agrees to the personal data privacy terms set out in the Company's Notice of EGM dated 8 October 2026.
- Please read the notes overleaf which contain instructions on, *inter alia*, the appointment of a proxy(ies) by a S-Share Shareholder to attend, speak and vote on his/her/its behalf at the EGM.

I/We*, _____ (Name) with

NRIC/Passport/Company Registration Number _____

of _____ (Address)

being a member/members of Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited (the "Company"), hereby appoint:

Name	NRIC/Passport Number	Proportion of Shareholdings	
		No. of Shares	%
Address			

and/or* (delete as appropriate)

Name	NRIC/Passport Number	Proportion of Shareholdings	
		No. of Shares	%
Address			

or failing whom, or if no persons are named above, the Chairman of the Extraordinary General Meeting as my/our* proxy/proxies* to attend, speak and vote for me/us* on my/our* behalf at the Extraordinary General Meeting of the Company ("EGM") to be held at the meeting room of Da Ren Tang Mansion, No. 17 Baidi Road, Nankai District, Tianjin, the PRC 300193 (concurrently, via video conferencing at 171 Chin Swee Road, CES Centre, #02-07/08, Singapore 169877 for S-Share Shareholders in Singapore) on Friday, 23 October 2026 at 2:00 p.m. and at any adjournment thereof.

I/We* direct my/our* proxy/proxies* to vote on the resolution(s) to be proposed at the EGM as indicated hereunder. If no specific direction as to voting is given or in the event of any other matter arising at the EGM and at any adjournment thereof, the proxy/proxies* (except where the Chairman of the EGM has been appointed as proxy) may vote or abstain from voting at his/her/their discretion. **Where the Chairman of the EGM is appointed as proxy, and no specific instructions as to voting, or abstentions from voting are given, the appointment of the Chairman of the EGM as proxy for that resolution will be treated as invalid.**

(Voting will be conducted by poll. If you wish your proxy or proxies to exercise all your votes "For", "Against" or to "Abstain" from voting, please indicate with a tick (✓) or a cross (X) within the box provided. Alternatively, please indicate the number of votes as appropriate. If you mark the abstain box for a particular resolution, you are directing your proxy or proxies not to vote on that resolution on a poll and your votes will not be counted in computing the required majority on a poll.)

Resolution(s) relating to:	For	Against	Abstain
To consider and approve the proposed amendments to the Articles of Association of the Company and the application for changes in the industrial and commercial registration			

*Delete as appropriate

Dated this _____ day of _____ 2026

Total number of Shares in:	No. of Shares ^{Note 1}
(a) Depository Register	
(b) Register of Members	

Signature(s) of Shareholder(s) or
Common Seal of Corporate Shareholder

IMPORTANT: PLEASE READ NOTES OVERLEAF BEFORE COMPLETING THIS PROXY FORM

PROXY FORM

Notes:

1. Please insert the total number of Shares held by you. If you have Shares entered against your name in the Depository Register (as defined in Section 81SF of the Securities and Futures Act 2001 of Singapore), you should insert that number of Shares. If you have Shares registered in your name in the Register of Members of the Company, you should insert that number of Shares. If you have Shares entered against your name in the Depository Register and Shares registered in your name in the Register of Members, you should insert the aggregate number of Shares entered against your name in the Depository Register and registered in your name in the Register of Members. **If no number is inserted, this instrument of proxy will be deemed to relate to all the Shares held by you.**
2. A Shareholder (whether individual or corporate, including Relevant Intermediaries (as defined in the Notice of EGM)) who is entitled to attend and vote at the EGM may appoint one (1) or more persons (who need not also be Shareholder(s)) to act as his/her/its proxy(ies) to attend and vote on his/her/its behalf at the EGM. Where a Shareholder appoints more than one (1) proxy, the appointment shall be deemed to be alternative unless he/she/it specifies the proportion of his/her/its shareholding (expressed as a percentage of the whole) to be represented by each proxy.

If the appointor is a corporation, the instrument of proxy must be executed under seal or by the hand of its duly authorised officer or attorney.

A S-Share Shareholder (whether individual or corporate) can also choose to appoint the Chairman of the EGM as his/her/its proxy, but this is not mandatory. The Chairman of the EGM, as proxy, need not be a Shareholder of the Company. Where a S-Share Shareholder (whether individual or corporate) appoints the Chairman of the EGM as his/her/its proxy, he/she/it must give specific instructions as to voting, or abstentions from voting, in this Proxy Form. **In the absence of specific instructions, the appointment of the Chairman of the EGM as his/her/its proxy for that resolution will be treated as invalid.**

Where a S-Share Shareholder (whether individual or corporate) appoints one (1) or more persons (other than the Chairman of the EGM) as his/her/its proxy(ies), he/she/it must give specific instructions as to voting, or abstentions from voting, in this Proxy Form. **In the absence of specific instructions, the proxy(ies) may vote or abstain from voting on the resolution(s) at his/her/their discretion;**

3. CPF Investors and/or SRS Investors (as applicable) who wish to vote should inform their respective CPF Agent Banks and/or SRS Operators to submit their votes at least **seven (7)** working days before the date of the EGM (i.e. by **5:00 p.m.** on **Tuesday, 13 October 2026**). **This Proxy Form is not valid for use by CPF Investors and SRS Investors and shall be ineffective for all intents and purposes if used or purported to be used by them.**
4. The duly completed Proxy Form must be submitted by S-Share Shareholders to the Company in the following manner:
 - (a) if submitted by post, be lodged with the Company's S-Shares Registrar and Singapore Transfer Office, Boardroom Corporate & Advisory Services Pte. Ltd., at 1 Harbourfront Avenue, Keppel Bay Tower #14-07, Singapore 098632; or
 - (b) if submitted electronically, via email to the Company's S-Shares Registrar and Singapore Transfer Office at srs.proxy@boardroomlimited.com,

in either case, by no later than **2:00 p.m.** on **Wednesday, 21 October 2026**.

S-Share Shareholders are strongly encouraged to submit completed Proxy Forms electronically via email.

A S-Share Shareholder who wishes to submit an instrument of proxy must first complete and sign the Proxy Form, before submitting it by post to the address provided above, or before scanning and sending it by email to the email address provided above. If a S-Share Shareholder is a corporation, the instrument of proxy must be executed under seal or by the hand of its duly authorised officer or attorney. Where an instrument appointing a proxy(ies) and/or representative(s) is signed on behalf of the appointor by an attorney, the letter or power of attorney or a duly certified copy thereof must (failing previous registration with the Company) be lodged with the instrument of proxy, failing which the instrument may be treated as invalid.

5. The completion and return of the instrument appointing a proxy(ies) by a Shareholder does not preclude such Shareholder from attending, speaking and voting in person at the EGM if such Shareholder subsequently decides to do so. The appointment of the proxy(ies) for the EGM will be deemed to be revoked if the Shareholder attends the EGM in person and in such event, the Company reserves the right to refuse to admit any person or persons appointed under the relevant instrument appointing a proxy(ies) to the EGM.

General:

The Company shall be entitled to reject the instrument appointing a proxy or proxies if it is incomplete, improperly completed, illegible, or where the true intentions of the appointor are not ascertainable from the instructions of the appointor specified in the instrument appointing a proxy or proxies. In addition, in the case of S-Share Shareholders whose Shares are deposited with The Central Depository (Pte) Limited ("**CDP**"), the Company shall be entitled to reject any such instrument appointing a proxy or proxies lodged if such S-Share Shareholder, being the appointor, is not shown to have Shares entered against his/her/its name in the Depository Register as at forty-eight (48) hours before the time appointed for holding the EGM, as certified by the CDP to the Company.

Personal data privacy:

By submitting an instrument appointing a proxy(ies) and/or representative(s), S-Share Shareholders accept and agree to the personal data privacy terms set out in the Notice of EGM dated 8 October 2026.

This page has been intentionally left blank.

